Mega Lifesciences Public Company Limited Asset Resilience Ratio
Mega Lifesciences Public Company Limited asset resilience ratio. Mega Lifesciences Public Company Limited (MEGA-R) has an Asset Resilience Ratio of 2.45% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mega Lifesciences Public Company Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mega Lifesciences Public Company Limited (2012–2024)
Asset resilience ratio of Mega Lifesciences Public Company Limited from 2012 to 2024. This chart shows how Mega Lifesciences Public Company Limited's Asset Resilience Ratio has changed over time. Read MEGA-R total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mega Lifesciences Public Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MEGA-R total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 0% |
| Short-term Investments | ฿350.06 Million | 2.45% |
| Total Liquid Assets | ฿350.06 Million | 2.45% |
Asset Resilience Insights
- Limited Liquidity: Mega Lifesciences Public Company Limited maintains only 2.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mega Lifesciences Public Company Limited Industry Peers by Asset Resilience Ratio
Compare Mega Lifesciences Public Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Mega Lifesciences Public Company Limited Asset Resilience Ratio by Year (2012–2024)
Mega Lifesciences Public Company Limited asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for Mega Lifesciences Public Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.47% | ฿350.30 Million ≈ $10.92 Million |
฿14.21 Billion ≈ $442.92 Million |
+0.02pp |
| 2023-12-31 | 2.45% | ฿355.52 Million ≈ $11.08 Million |
฿14.52 Billion ≈ $452.56 Million |
+0.16pp |
| 2022-12-31 | 2.29% | ฿335.41 Million ≈ $10.45 Million |
฿14.65 Billion ≈ $456.52 Million |
-0.22pp |
| 2021-12-31 | 2.51% | ฿333.66 Million ≈ $10.40 Million |
฿13.27 Billion ≈ $413.67 Million |
+0.69pp |
| 2020-12-31 | 1.82% | ฿211.09 Million ≈ $6.58 Million |
฿11.59 Billion ≈ $361.24 Million |
-0.15pp |
| 2019-12-31 | 1.97% | ฿207.14 Million ≈ $6.46 Million |
฿10.53 Billion ≈ $328.30 Million |
-1.85pp |
| 2018-12-31 | 3.81% | ฿367.33 Million ≈ $11.45 Million |
฿9.63 Billion ≈ $300.24 Million |
-4.18pp |
| 2017-12-31 | 7.99% | ฿696.75 Million ≈ $21.72 Million |
฿8.72 Billion ≈ $271.79 Million |
-0.22pp |
| 2016-12-31 | 8.21% | ฿651.66 Million ≈ $20.31 Million |
฿7.94 Billion ≈ $247.51 Million |
-4.29pp |
| 2015-12-31 | 12.49% | ฿951.11 Million ≈ $29.65 Million |
฿7.61 Billion ≈ $237.28 Million |
+6.04pp |
| 2014-12-31 | 6.45% | ฿433.83 Million ≈ $13.52 Million |
฿6.72 Billion ≈ $209.53 Million |
+6.12pp |
| 2013-12-31 | 0.33% | ฿21.49 Million ≈ $669.89K |
฿6.54 Billion ≈ $203.72 Million |
+0.20pp |
| 2012-12-31 | 0.12% | ฿5.17 Million ≈ $161.08K |
฿4.14 Billion ≈ $128.89 Million |
-- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more